Novartis to pay up to $1.75 billion for U.S. cancer-focused biotech
By Steve Goldstein
Pharmaceutical giant Novartis AG on Thursday said it will pay up to $1.75 billion for a U.S. biotech focused on cancer.
Novartis said it's paying $1 billion upfront and up to $750 million more in milestone payments for Mariana Oncology, a Watertown, Mass.-based preclinical-stage biotechnology company focused on cancers with high unmet patient needs.
Mariana Oncology is working on developing what's called radioligand therapies, or RLT, and is investigating a candidate for use in small-cell lung cancer.
Novartis has two approved RLTs for certain patients with metastatic castration-resistant prostate cancer and certain types of gastroenteropancreatic neuroendocrine tumors.
Novartis shares in Swiss trade (CH:NOVN) (NVS) were steady and have gained 5% this year.
-Steve Goldstein
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
05-02-24 0718ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
What’s Happening In the Markets This Week
-
What Does Nvidia’s Stock Split Mean for Investors?
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Best- and Worst-Performing Stocks of May 2024
-
3 Stocks to Buy and 3 Stocks to Sell in June
-
Apple: Generative AI Strategy Should Drive Sales and Upgrades
-
2 Undervalued Stocks That Just Raised Dividends
-
2 Popular Stocks That Top Managers Are Selling
-
The Best REITs to Buy
-
Nio Earnings: Revenue and Loss Largely In Line, but Vehicle Margin Missed Amid Price Competition
-
The Best Biotech Stocks to Buy
-
After Earnings, Is Marvell Stock a Buy, a Sell, or Fairly Valued?
-
Nvidia Raised Its Dividend — but There’s a Catch